IPO Timeline
Broker Results (T-2)
2020-05-20
Some brokers release in afternoon
Grey Market (T-1)
2020-05-21
Afternoon
HKEX Allotment (T-1)
2020-05-21
Evening
Registrar Allotment (T-1)
2020-05-21
Evening
Listing Day (T)
2020-05-22
First day of trading
Company Overview
| Stock Name | 開拓藥業有限公司 - B |
|---|---|
| Stock Code | 09939 |
| Company Full Name | 開拓藥業有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事研發藥產品業務，專注於開發及商業化癌癥藥物及其他雄激素受體相關疾病藥物。 |
| Listing Date | 2020-05-22 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園C4幢401室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.kintor.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 20.15 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 47.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 930,406,100 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 21.5 |
|---|---|
| First Day Open | HK$ 20.15 |
| First Day Change | 6.70% |
| First Day Volume | 68937600.0 |
| First Day Turnover | 1484110000.0 |
Use of Proceeds
| Use of Proceeds | 1、約42%所得款項凈額（約734.0百萬港元）分配至我們的其中一種核心產品普克魯胺的開發及商業化； 2、約28%所得款項凈額（約489.3百萬港元）分配至我們的其中一種核心產品福瑞他恩的開發及商業化； 3、約4%所得款項凈額（約69.9百萬港元）分配至開發我們的臨床階段在研藥物ALK-1； 4、約4%所得款項凈額（約69.9百萬港元）分配至開發我們的臨床階段在研藥物迪拓賽替； 5、約4%所得款項凈額（約69.9百萬港元）分配至開發我們的臨床階段在研藥物GT1708F（Hedgehog/SMO抑制劑）； 6、約2%所得款項凈額（約35.0百萬港元）分配至其他臨床研究項目； 7、約6%所得款項凈額（約104.8百萬港元）分配至我們臨床前階段在研藥物的研發； 8、約10%所得款項凈額（約174.7百萬港元）分配至我們的營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
华泰金融控股（香港）有限公司 CE AOK809
Overall Coordinators (3)
华泰金融控股（香港）有限公司 CE AOK809
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (8)
华泰金融控股（香港）有限公司 CE AOK809
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
华兴证券（香港）有限公司 CE AZX839
海通国际证券有限公司 CE AAF806
建银国际金融有限公司 CE AJO225
中国光大证券（香港）有限公司 CE AAW536
Joint Lead Managers (11)
华泰金融控股（香港）有限公司 CE AOK809
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
华兴证券（香港）有限公司 CE AZX839
海通国际证券有限公司 CE AAF806
建银国际金融有限公司 CE AJO225
中国光大证券（香港）有限公司 CE AAW536
浦银国际融资有限公司 CE BFZ375
富途证券国际（香港）有限公司 CE AZT137
阿尔法国际证券(香港)有限公司
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Cherry Cheeks HK Limited | 54,253,875 HKD | — | 2.92% | — | 6 months | 2020-11-22 |
| 2 | Foresight Orient Global Superior Choice SPC | 38,748,450 HKD | — | 2.08% | — | 6 months | 2020-11-22 |
| 3 | Highlight Medical Limited | 38,748,450 HKD | — | 2.08% | — | 6 months | 2020-11-22 |
| 4 | 珠海格力金融投资管理有限公司 | 759,584,475 HKD | — | 40.82% | — | 6 months | 2020-11-22 |
Directors & Management
| Chairman | 童友之 |
|---|---|
| Company Secretary | 黃偉超;章明明 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 童友之(9.05%);郭創新(9.84%);珠海格力金融投資管理有限公司(6.77%) |
|---|
IPO Timeline
